$NPCE News

HC Wainwright & Co. Reiterates Buy on NeuroPace, Maintains $20 Price Target

NeuroPace, Inc. (NPCE) Discusses FDA Feedback on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy Transcript

NeuroPace Asked To Submit Submission Issue Request By FDA For Its RNS System To Include Patients With Antiseizure Medication-Resistant Idiopathic Generalized Epilepsy; FDA Indicated PMA Supplment Not Approvable In Current Form

Mizuho Initiates Coverage On NeuroPace with Outperform Rating, Announces Price Target of $22

NeuroPace, Inc. (NPCE) Reveals FDA Approval of ECoG Assistant™

Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 27.88%: Here's is How to Trade

NeuroPace (NPCE) Down 0.6% Since Last Earnings Report: Can It Rebound?

How The NeuroPace (NPCE) Investment Story Is Shifting Without A New Analyst Price Target

NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting

NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care

NeuroPace To Highlight Expanding Role Of Responsive Neuromodulation In Epilepsy Care In 2026 ASSFN Meeting

HC Wainwright & Co. Maintains Buy on NeuroPace, Raises Price Target to $20

NeuroPace (NPCE) Q1 2026 Earnings Transcript

NeuroPace, Inc. (NASDAQ:NPCE) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

NeuroPace, Inc. Q1 2026 Earnings Call Summary

NeuroPace Inc (NPCE) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ...

NeuroPace Q1 Earnings Call Highlights

NeuroPace, Inc. (NPCE) Q1 2026 Earnings Call Transcript

NeuroPace (NASDAQ:NPCE) Beats Q1 Estimates, Raises Full-Year Revenue Guidance

NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance